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TRIM5α acts on several retroviruses, including human immunodeficiency virus (HIV-1), to restrict cross-species transmission. Using natural
history cohorts and tissue culture systems, we examined the effect of polymorphism in human TRIM5α on HIV-1 infection. In African Americans,
the frequencies of two non-coding SNP variant alleles in exon 1 and intron 1 of TRIM5 were elevated in HIV-1-infected persons compared with
uninfected subjects. By contrast, the frequency of the variant allele encoding TRIM5α 136Q was relatively elevated in uninfected individuals,
suggesting a possible protective effect. TRIM5α 136Q protein exhibited slightly better anti-HIV-1 activity in tissue culture than the TRIM5α
R136 protein. The 43Y variant of TRIM5α was less efficient than the H43 variant at restricting HIV-1 and murine leukemia virus infections in
cultured cells. The ancestral TRIM5 haplotype specifying no observed variant alleles appeared to be protective against infection, and the
corresponding wild-type protein partially restricted HIV-1 replication in vitro. A single logistic regression model with a permutation test indicated
the global corrected P value of <0.05 for both SNPs and haplotypes. Thus, polymorphism in human TRIM5 may influence susceptibility to HIV-1
infection, a possibility that merits additional evaluation in independent cohorts.
© 2006 Elsevier Inc. All rights reserved.Keywords: TRIM5α; Single nucleotide polymorphism; HIV-1; HIV infections; Disease susceptibility; Genetics; HaplotypeIntroduction
A major barrier to cross-species transmission of retroviruses
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doi:10.1016/j.virol.2006.06.0312002; Stremlau et al., 2004). Variants of TRIM5α in different
primate species block the early, post-entry phase of infection of
cells by particular retroviruses (Hatziioannou et al., 2004b;
Keckesova et al., 2004; Perron et al., 2004; Yap et al., 2004b).
For example, even when expressed at comparable levels, human
TRIM5α (TRIM5αhu) is less potent at suppressing infection of
human immunodeficiency virus (HIV-1) than the rhesus monkey
ortholog, TRIM5αrh (Hatziioannou et al., 2004b; Keckesova et
al., 2004; Stremlau et al., 2004; Yap et al., 2004a). On the other
hand, TRIM5αhu more potently restricts infection by the N-
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(Hatziioannou et al., 2004b; Perez-Caballero et al., 2005; Perron
et al., 2004; Song et al., 2005c; Stremlau et al., 2004; Yap et al.,
2004a).
TRIM5 is a member of a family of proteins that contain a
tripartite motif, hence the designation TRIM (Reymond et al.,
2001). TRIM proteins have also been called RBCC proteins
because the tripartite motif includes a RING domain, B-box 2
domain and coiled coil domain. TRIM proteins exhibit the
propensity to assemble into cytoplasmic or nuclear bodies
(Reymond et al., 2001). Many cytoplasmic TRIM proteins
contain a C-terminal B30.2 or SPRY domain. Differential
splicing of the TRIM5 primary transcript gives rise to the
expression of several isoforms of the protein product. The
TRIM5α isoform is the largest product (∼493 amino acid
residues in humans) and contains the B30.2(SPRY) domain.
The B30.2(SPRY) domain of rhesus monkey TRIM5α is
essential for anti-HIV-1 activity (Stremlau et al., 2005).
Moreover, the difference in the anti-HIV-1 potency of rhesus
and human TRIM5α proteins is determined by B30.2(SPRY)
sequences (Perez-Caballero et al., 2005; Stremlau et al., 2005;
Yap et al., 2005). An intact RING domain also contributes,
either directly or indirectly, to the antiretroviral activity of
TRIM5αrh and TRIM5αhu (Javanbakht et al., 2005; Perez-
Caballero et al., 2005; Stremlau et al., 2005). The B-box 2
domain appears to be essential for efficient retrovirus restriction
(Javanbakht et al., 2005; Perez-Caballero et al., 2005).
Interspecies differences in primate TRIM5α proteins dictate
the potency of restriction against particular retroviruses
(Hatziioannou et al., 2004b; Keckesova et al., 2004; Song et
al., 2005c; Stremlau et al., 2004; Yap et al., 2004a). The effect of
intraspecies variation in TRIM5α on antiretroviral potency is
unknown. Moreover, it is uncertain whether the modest
inhibitory effect of TRIM5αhu on HIV-1 infection in tissue-
cultured cells translates into any limiting effect on HIV-1
infection of humans. Functional polymorphisms in human
TRIM5 that correlate with differential susceptibility to HIV-1
infection or disease progression would support an interaction of
TRIM5αhu with HIV-1 in vivo. We therefore studied the
influence of human TRIM5 polymorphisms on HIV-1 infection
and progression to AIDS in five U.S.-based natural history
cohorts, an approach that has identified several other AIDS-
modifying host variants (An et al., 2004; Dean et al., 1996;
O'Brien et al., 2000). We also investigated the antiretroviral
activity in tissue-cultured cells of common and several rare
TRIM5αhu variants.
Results
Identification of human TRIM5 single nucleotide
polymorphisms (SNPs)
Common and rare TRIM5 SNPs were identified in the
human TRIM5 gene using the SNP discovery panel (n=188),
representing the extremes of the distribution for HIV-1
progression and infection, and from 359 normal blood donors
and CEPH family founders, the Human Diversity Panel(n=368), at-risk HIV-1-uninfected individuals (n=344), and
HIV-1-infected persons from the 5 U.S.-based natural history
cohorts (n=698) and from South African HIV-1-infected and
-uninfected Xhosa (n=272). The SNP discovery panel of 188
DNA samples was re-sequenced across all exons and intron–
exon boundaries, and the other groups were re-sequenced for
exon 2 encoding the RING domain and exon 8 encoding the
B30.2(SPRY) domain. In addition, DNAs from persons
progressing to AIDS in 5 or less years were re-sequenced for
coding exons 2, 3, 8 and intron 6 and at-risk HIV-1-uninfected
individuals were re-sequenced for exons 2, 3 and 8.
Twelve TRIM5 SNPs having allele frequencies of >5% in
either European Americans (EA) or African Americans (AA)
were identified either by re-sequencing and/or from the NCBI
dbSNP database; these common SNPs are listed in Table 1 and
their locations indicated in Fig. 1. Of the 6 open reading frame
(ORF) SNPs, 5 were non-synonymous and one was synon-
ymous. For SNP4, SNP9 and SNP11, the minor alleles in AA
were the major alleles in EA. These three SNPs also had the
highest Fst (a measure of population differentiation) ranging
from 0.23 to 0.35 (Supplementary Table 1). The remaining
SNPs had Fst values ranging from 0.002 to 0.16 compared to an
average Fst of 0.12 across the autosomes (Altshuler et al.,
2005).
We also re-sequenced a large number of subjects to identify
variant alleles in other populations (human diversity panel and
the South African Zhosa) as well as participants enrolled in the
AIDS cohorts with unusual patterns of progression (unusually
rapid or slow progression). Nearly all of these additional variant
alleles were infrequent and are listed in Table 2. In the Zhosa,
only one variant allele had a frequency in the 4–5% range. Two
non-synonymous SNPs were observed in only the Xhosa
population. P479L was polymorphic in both HIV-1-infected
(minor allele frequency (MAF) ≈5%) and -uninfected Xhosa
(MAF ≈4%) but was observed only once in a European
American. Because these SNPs are rare, their possible effects on
infection or progression could not be assessed: SNP distribution
between HIV-1 seronegatives and seropositives are listed in
Table 2.
Selection on TRIM5
Perturbations in the allele frequency spectrum can reflect
relatively recent selective episodes. The SNP discovery panel
(unambiguous DNA sequences for all exons were available for
155 subjects) suggests a scarcity of low frequency polymorph-
ism (range 1–5%) TRIM5α SNP alleles (6.5% for H43Y, 6.1%
for Y112F, 26.8% for R136Q, 20% for L159L, 12.9% for
G249D and 1.9% for H419Y) throughout the 1.5-kb protein-
coding segment. However, the large screen (Table 2) contained
a number of rare variant alleles at frequencies less than 1%. The
allele spectrum does not deviate significantly from neutrality—
Tajima's D=−1.306 (P>0.1).
Past or ongoing selection might also be revealed in the ratio
of synonymous to non-synonymous changes. In humans, only 5
of 24 coding region variants are synonymous (Tables 1 and 3)
and only 2 of 17 substitutions found between human and
Table 1
Characterization of TRIM5α SNPs and their allele frequencies in HIV-1 risk groups
No. a SNPb nt change c aa
change d
Location Domain Minor allele frequency in AA Allele frequency in EA
SC e SN f HREUg P value h Q value i SC SN HREU P value Q value
1 rs3802980 T/C 5′ Upstream 0.438 0.398 0.424 0.427 0.861 0.483 0.475 0.475 0.734 0.861
2 rs16934386 T/C Exon 1 0.112 0.080 0.045 0.006 0.130 0.002 0.000 0.004 0.762 0.861
3 rs7127617 T/C Intron 1 0.479 0.441 0.391 0.038 0.280 0.466 0.474 0.467 0.845 0.875
4 rs3824949 C/G 5′ UTR 0.165 0.187 0.203 0.211 0.861 0.549 0.550 0.504 0.254 0.861
5 rs3740996 CAC>TAC H43Y Exon 2 RING 0.060 0.087 0.095 0.063 0.350 0.114 0.114 0.101 0.608 0.861
6 rs11601507 GTC>TTC V112F Exon 2 B-box 2 0.014 0.009 0.013 0.690 0.861 0.078 0.063 0.089 0.950 0.875
7 rs10838525 CGG>CAG R136Q Exon 2 Coil 0.114 0.131 0.188 0.024 0.260 0.354 0.372 0.352 0.744 0.861
8 rs3740995 TTG>TTA L159L Exon 3 Coil 0.285 0.308 0.228 0.424 0.861 0.143 0.134 0.141 0.779 0.861
9 rs904375 A/G Intron 4 0.448 0.457 0.423 0.757 0.861 0.823 0.841 0.810 0.934 0.875
10 rs11038628 GGT>GAT G249D Exon 5 Linker 2 0.274 0.259 0.237 0.329 0.861 0.063 0.060 0.074 0.651 0.861
11 rs11820502 G/C Intron 5 0.216 0.210 0.215 0.922 0.875 0.703 0.730 0.707 0.543 0.861
12 rs28381981 CAT>TAT H419Y Exon 8 B30.2 0.010 0.013 0.013 0.719 0.861 0.060 0.055 0.057 0.733 0.861
a Number corresponds to SNPs in Fig. 1, tables and text.
b Reference number from NCBI dbSNP.
c Nucleotide (nt) change is ordered by major/minor allele in AA and based on the forward sequences (AC109341 and NM_033034).
d Predicted amino acid replacement for non-synonymous SNPs. The amino acid encoded by the major allele in AA precedes the residue number, which is followed
by the amino acid encoded by minor allele. Note that for SNPs 4, 9 and 11, the minor allele in AA is the major allele in EA.
e HIV-1+ seroconverter.
f HIV-1 seronegative belonging to an HIV-1 risk group.
g High-risk exposed HIV-1 uninfected.
h P values are from Mantel–Haenszel test for trend for the three groups (SC, SN and HREU), in AA or EA, respectively. The P values have not been corrected for
multiple comparisons.
i The false discovery Q value is the proportion of statistical tests deemed significant that are actually false positives.
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synonymous substitution (0.0146 substitutions per site by Li's
1993 method for human–chimpanzee comparisons) exceeds
that of synonymous (0.00383 substitutions per site). However,
the excess of non-synonymous substitution is not sufficient to
implicate diversifying selection (P>0.1 in Fisher's exact test
using the modified Nei–Gojobori method of synonymous site
counting).
Effect of TRIM5 SNPs on susceptibility to HIV-1 infection
The effects of the 12 TRIM5 SNPs on susceptibility to HIV-1
infection were tested by comparing allele frequencies among
three HIV-1 risk groups with increasing HIV-1 risk levels: high-
risk exposed HIV-1-uninfected individuals (HREU), HIV-1
seronegatives (SN) and HIV-1-infected seroconverters (SC)
using the Mantel–Haenszel trend test. SNP2, SNP3 and SNP7Fig. 1. SNP locations in the human TRIM5 gene. Black boxes correspond to the TRIM
(not drawn to scale) with exon numbers indicated above. Locations of SNPs with nuc
are indicated by vertical lines. Domain structure of the TRIM5α protein is shown belo
genomic sequence (accession number AC109341) and the mRNA reference sequenhad differences (P=0.006, 0.038 and 0.024, respectively) in
allele frequencies among the three groups and SNP5 (43Y)
showed a tendency to be more frequent in SN (P=0.063) (Table
1) in African Americans. No differences in allele frequencies
were observed in European Americans (0.25<P≤0.95).
To assess the influence of multiple tests shown in Table 1,
we estimated the false discovery rate (FDR) Q value, which
is defined as the proportion of statistical tests deemed
significant that are actually false positives. The Q values are
shown in Table 1 for all the SNPs. For the three SNPs
showing uncorrected P values less than 0.05, the FDR
ranged from 13% to 28%, and for H43Y the FDR was 35%.
For all other SNPs in AA and EA, the FDR was greater than
86%.
The genotypic distribution of the four SNPs showing the
lowest P values for all at-risk HIV-1 SN or HREU compared
to HIV-1+ seroconverters in AA, in each case comparing5 gene open reading frame, and white boxes represent the untranslated regions
leotide changes and corresponding amino acid (aa) changes in protein sequence
w. The genomic structure of TRIM5 was predicted based on the comparison of a
ce (NM_033034).
Table 2
TRIM5α variants identified by re-sequencing selected exons a
Codon b Exon South African Xhosa c Large screen d
HIV+ Blood donors HIV+ HIV− Donors
n=193
(frequency)
n=79
(frequency)
n=611 n=616 n=820
C58Y 2 NDe ND 0 1 0
V77A 2 ND ND 1 0 0
D93V 2 ND ND 1 0 0
G110E 2 ND ND 2 6 1
R119W 2 ND ND 1 0 0
Q143R 3 ND ND 1 0 ND
V140L 3 ND ND 0 1 ND
R229R 4 ND ND 1 0 ND
128625G/C f Intron 5 ND ND 1g 0 ND
K396K 6 ND ND 0 0 2
V423F 8 0 0 1 0 0
V438G 8 0 0 0 0 1
Y444C 8 0 0 1 0 0
A446S h 8 2 (0.005) i 1 (0.006) 0 0 0
I461L 8 0 0 0 2 0
S470P 8 0 0 1 0 0
P475Ph 8 3 (0.008) i 1 (0.006) 0 0 0
P479L 8 20 (0.052) i 7 (0.044) 1 0 0
a The lists of all variant alleles observed by re-sequencing that are not listed in
Table 1. With the exception of P479L in the Zhosa, all the variants have
frequencies <1%.
b Predicted amino acid replacement for non-synonymous SNPs. The wild-
type (wt) TRIM5αhu protein has the sequence reported in Stremlau et al. (2004).
The amino acid residue found in wt TRIM5αhu precedes the residue number,
which is followed by the amino acid residue found in the variant TRIM5αhu
protein.
c 193 HIV-1-seropositive patients from clinics in the Western Cape Province
of South Africa and 79 HIV-1-seronegative controls who are blood donors from
the Western Province Blood Transfusion Service (Petersen et al., 2005).
d See Materials and methods for the number of individuals re-sequenced for
each exon. The HIV-1-seropositive and -seronegative groups are from the 5 U.
S.-based natural history cohorts. The donors are from the CEPH founders,
Human diversity panel, and normal blood donors.
e Not determined.
f Located at nt. 128625 on sequence AC109341.
g This individual survived AIDS free for >16 years.
h Observed only in the Xhosa population.
i The Fisher exact test was used for determining allele frequency differences
between Xhosa HIV-1-seropositive and -seronegative groups, with P>0.80.
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homozygotes for the minor allele (Table 3). The frequencies
for the minor alleles of SNP2 and SNP3 were elevated in the
SC group relative to either the SN group or the HREU group,
implicating these SNPs as possible risk factors for HIV-1
infection (Table 3). Two non-synonymous SNPs were more
frequent in uninfected persons. The 43Y allele (SNP5) was
elevated in uninfected persons (OR=0.61, P=0.043) and the
136Q allele (SNP7) was elevated in the HREU group
(OR=0.52, P<0.02, dominant model) (Table 3). SNP5
(H43Y) and 7 (R136Q) are both in exon 2 encoding the
RING and coiled coil domains, respectively (Table 1; Fig. 1).
The same analyses were also performed in EA; however,
alleles and genotype frequencies were evenly distributed in
each of three infection status groups, with no associations
observed with HIV-1 infection (Table 1).Effect of TRIM5 haplotypes on susceptibility to HIV-1 infection
Pairwise LD of the 12 common TRIM5 SNPs in AA and EA
is presented in Supplementary Figs. 1A and B and inferred
haplotypes are listed in Supplementary Table 1. A low degree of
D′, a measure of linkage disequilibrium (range=0–1.0, mean
comparing to SNP1=0.50 in AA; range=0.03–1.0, mean=0.69
in EA), and r2, a measure of correlation, (range=0.001–0.43
and 0.001–0.75 for AA and EA, respectively) were observed
for many of the SNP pairs.
An analysis was performed for haplotypes inferred from the
12 SNPs. In AA, a protective effect on infection was observed
only for haplotype 2 when comparing SC to SN or HREU
(OR=0.50, 0.59, P=∼0.02) (Supplementary Table 2). In AA,
there are 7 haplotypes that carry all of themajor frequency amino
acids, but varying at the non-coding SNPs. Haplotype 2, the
most frequent, also carries major frequency nucleotides at the
non-coding sites, suggesting that this haplotype may be
ancestral. In EA, haplotype 2 was too infrequent (freq.
≈0.6%) to be tested. No other significant associations between
haplotypes and either progression or infection were observed for
either EA or AA.
To determine if the susceptibility-enhancing effects of the
SNP2 T/C and SNP3 T/C and the protective effects of SNP5 C/T
(H43Y) and SNP7 G/A (R136Q) variant alleles were indepen-
dent, we considered the haplotype structure for the SNP pairs.
The variant alleles for SNP pair 2 and 3 and for SNP pair 5 (43Y)
and 7 (136Q) are in strong negative LD (D′=0.9, 1.0,
respectively) and therefore rarely occur together on the same
haplotype (for SNP2–SNP3, the haplotypes are T-T, C-T and T-
C); for SNP5–SNP7, the haplotypes are C-G, T-G and C-A)
(Table 4). This indicates that the susceptibility-enhancing effects
of the SNP2 and SNP3 variant alleles and the protective effects of
43Y and 136Q are independent. We formally tested the
independent predictive value of the variant haplotypes using
multivariate logistic regression, testing association with increas-
ing resistance to HIV-1 infection (HREU<SN<SC) under the
proportional odds model. For each 2-SNP haplotype, the model
was adjusted for the effects of the other variant haplotype (i.e., the
effects of haplotype C-Twas adjusted for the effects of haplotype
T-C). For SNP2 and SNP3, the variant alleles were independent
risk predictors of infection (SNP2C: OR=1.85;P=0.007; SNP3
C: OR=1.56, P=0.01). Similarly, both SNP5 and SNP7 variant
alleles were associated with decreased risk of infection (SNP5 T:
OR=0.61, P=0.03; SNP7 A: OR=0.65, P<0.02).
As correction for multiple comparisons is not straightfor-
ward when there are multiple significant results before
correction, in particular when the results are for genetic factors
in LD (thus correlated), we tested for overall significance of the
associations by a permutation test, simulating the null
hypothesis of TRIM5 variants having no effect on infection.
Here we tested the simplest a priori alternate hypothesis, that
any effects would be additive for the genetic factors and
progressive in susceptibility to infection. We ran a proportional
odds logistic regression with TRIM5 SNPs as explanatory
variables and ordinal susceptibility to infection as the outcome
variable. SNPs with minor allele frequency <0.05 were omitted.
Table 3
The effects of selected TRIM5α SNPs a on HIV-1 infection in AA
SNP Group Number Total Genotype frequency SC cases vs. SN or HREU controls
11 12 22 OR (95% CI) b Puncorrected
c
TT TC CC TC+CC vs. TT
SNP2 rs16934386 SC 222 57 4 283 0.785 0.201 0.014 1
All SN 266 40 2 308 0.864 0.130 0.007 1.74 (1.12–2.70) 0.011
HREU 70 7 0 77 0.909 0.091 0.000 2.75 (1.20–6.25) 0.013
TT TC CC TC+CC vs. TT
SNP3 rs7127617 SC 65 131 55 251 0.259 0.522 0.219 1
All SN 98 121 63 282 0.348 0.429 0.223 1.52 (1.05–2.22) 0.027
HREU 29 30 15 74 0.392 0.405 0.203 1.85 (1.06–3.22) 0.027
CC TC TT TC+TT vs. CC
SNP5 H43Y SC 250 30 2 282 0.887 0.106 0.007 1
All SN 250 50 2 302 0.828 0.166 0.000 0.61 (0.38–0.99) 0.043
HREU 63 14 0 77 0.818 0.182 0.000 0.57 (0.29–1.15) 0.110
GG G/A AA AG+AA vs. GG
SNP7 R136Q SC 224 59 4 295 0.759 0.200 0.014 1
All SN 310 101 9 420 0.738 0.240 0.021 0.79 (0.56–1.16) 0.198
HREU 52 26 2 80 0.650 0.325 0.025 0.52 (0.30–0.89) 0.017
a All SNPs showing an uncorrected P value of <0.050.
b OR is the odds ratio of being an HIV-1-infected seroconverter compared to being either HIV-1-seronegative (All SN) or high-risk exposed HIV-1 uninfected
(HREU).
c P values are not corrected for multiple comparisons.
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permutations of the data, 65 out of 5000 permutations showed
an AIC as low as that (1257.98) observed for the actual data,
indicating an overall significance of TRIM5 associations with
infection in AA of 0.013. A corresponding test of haplotype
associations, using all haplotypes with frequency >0.05 in place
of the SNPs as additive explanatory variables in the logistic
regression, indicated a significance of 0.0224.
Correcting for the two races tested (but not for the two
analyses, SNP and haplotype, as these are non-independentTable 4
Effects of two-SNP haplotypes of TRIM5α on HIV-1 infection in African
Americans
Haplotype Haplotype
frequency
HREU<SN<SCa
OR (95%CI) Puncorrected
SNP2–SNP3
T-T 0.47 1 –
C-T 0.09 1.85 (1.18–2.90) 0.007
T-C 0.44 1.56 (1.11–2.20) 0.01
SNP5–SNP7 H43Y–R136Q
C-G (H-R) 0.79 1 –
T-G (Y-R) 0.07 0.61 (0.40–0.94) 0.03
C-A (H-Q) 0.14 0.65 (0.46–0.93) 0.02
P values are not corrected for multiple comparisons.
a HREU, SN and SC were coded as ordinal levels of increasing susceptibility
to HIV-1 infection in a proportional odds logistic regression. The independent
effects of the variant SNP2–SNP3 and SNP5–SNP7 haplotypes on suscept-
ibility to infection were assessed by considering them as regression covariates
in this model. The odds ratio (OR) is the effect of the haplotype on the odds of
being in a being in a more susceptible risk category.analyses with equivalent results), overall significances of 0.03
for an effect of TRIM5 SNPs and of 0.04 for TRIM5 haplotypes
on HIV-1 infection are indicated.
Effect of TRIM5 SNPs on AIDS progression
No associations were found for any of 12 common TRIM5
SNPs on progression to CD4<200, AIDS-defining conditions
or AIDS-related death, using Cox model analysis in AA
(n=295) or EA (n=644) seroconvertors (data not shown).
Effect of TRIM5α polymorphisms on antiretroviral activity
The contribution of each of the common and several of the
rare polymorphisms in the TRIM5αhu protein to antiretroviral
activity was studied. The “wild-type” TRIM5αhu protein for
these studies was that encoded by the TRIM5 allele reported in
Stremlau et al. (2004) and the amino acid change associated
with each variant was introduced into this wild-type (wt) protein
(Fig. 2A). The amino acid residues in the wild-type TRIM5α
protein are those encoded by the more frequent TRIM5 alleles.
The TRIM5αhu proteins possess C-terminal epitope tags
derived from influenza hemagglutinin (HA). LPCX retroviral
vectors expressing the TRIM5αhu variants were used to
transduce Cf2Th canine thymocytes. Recombinant viruses
were produced in 293T cells by cotransfecting the pLPCX
plasmids with the pVPack-GP and pVPack-VSV-G packaging
plasmids. The pVPack-VSV-G plasmid encodes the vesicular
stomatitis virus (VSV) G envelope glycoprotein, which allows
efficient entry into a wide range of vertebrate cells (Yee et al.,
Fig. 2. Sequence and expression of wild-type and mutant TRIM5αhu proteins. (A) A representation of the TRIM5αhu protein with the carboxy-terminal hemagglutinin
(HA) tag is shown, with the domains labeled and domain boundaries numbered according to the amino acid residue. Human TRIM5α polymorphic variants tested for
antiviral function are depicted beneath the wild-type TRIM5αhu protein. (B) Cf2Th cells stably expressing the wild-type and variant TRIM5αhu proteins were lysed.
Cell lysates were Western blotted and probed with antibodies directed against either the HA epitope tag (top panel) or β-actin (bottom panel). (C) Cf2Th cells
expressing the wild-type or variant TRIM5a proteins were grown overnight on 8-well chamber slides, fixed, permeabilized and incubated with rat anti-HA 3F10
antibody (Roche), followed by anti-rat IgG conjugated with FITC (Santa Cruz). Subsequently, samples were mounted for fluorescence microscopy.
20 H. Javanbakht et al. / Virology 354 (2006) 15–271994). The TRIM5αhu variants were expressed stably in the
transduced Cf2Th canine thymocytes. Because dogs do not
have a TRIM5 gene (Song et al., 2005a, 2005c), the use of
Cf2Th cells provides a neutral background for the assessment of
TRIM5αhu function. Western blotting of the cell lysates with an
anti-HA antibody indicated that all of the TRIM5αhu variants
were expressed at comparable levels (Fig. 2B). Staining of the
Cf2Th cells with the anti-HA antibody revealed diffuse
cytoplasmic staining as well as scattered cytoplasmic bodiesfor all of the variants (Fig. 2C and data not shown). All of the
TRIM5αhu variants exhibited staining patterns similar to that of
the wt TRIM5αhu protein, with one exception. The 43Y
TRIM5αhu variant formed more prominent cytoplasmic bodies
than the other TRIM5αhu variants (Fig. 2C).
To examine the susceptibility of the Cf2Th cells
expressing the TRIM5αhu variants to N-MLV infection, we
incubated the cells with the recombinant N-MLV-GFP virus.
This recombinant, single-round virus expresses green
Fig. 3. Effect of expression of the TRIM5αhu variants on N-MLV and B-MLV
infection. Cf2Th cells expressing the wild-type (wt) and mutant TRIM5α
proteins, or control Cf2Th cells transduced with the empty pLPCX vector, were
incubated with various amounts of N-MLV-GFP (A) or B-MLV-GFP (B). Cells
were washed and returned to culture for 48 h, and then subjected to FACS
analysis with a FACScan (Becton Dickinson). The results of a typical
experiment, which was repeated twice with comparable outcomes, are shown.
21H. Javanbakht et al. / Virology 354 (2006) 15–27fluorescent protein (GFP), allowing successfully infected
cells to be quantified (Fig. 3). Compared with Cf2Th cells
transduced with the empty pLPCX vector, Cf2Th cells
expressing the wt TRIM5αhu protein were strongly resistant
to N-MLV-GFP infection (Fig. 3A). Most of the TRIM5αhu
variants restricted N-MLV-GFP infection as efficiently as wt
TRIM5αhu. However, Cf2Th cells expressing the 43Y
TRIM5αhu variant were more susceptible to N-MLV-GFP
infection than cells expressing wt TRIM5αhu. Cf2Th cells
expressing the 112F TRIM5αhu variant were slightly more
infectible by N-MLV-GFP than cells expressing wt
TRIM5αhu. Thus, although both the 43Y and 112F variants
of TRIM5αhu retained the ability to restrict N-MLV-GFP
infection, these mutants were less efficient than the wt
TRIM5αhu protein and the other human variants tested.
To examine the ability of the TRIM5αhu variants to inhibit
HIV-1 infection, we incubated the Cf2Th cells expressing the wt
and mutant TRIM5αhu proteins and the control Cf2Th cells
transduced with the empty pLPCX vector with HIV-1-GFP.
Compared with the Cf2Th cells transduced with the pLPCX
vector, Cf2Th cells expressing the wt and mutant TRIM5αhu
proteins exhibited a modest reduction in susceptibility to
HIV-1-GFP infection. The level of HIV-1 restriction was similar
for the wt and mutant TRIM5αhu proteins, although the 43Yand
112F proteins were slightly less effective at blocking HIV-1
infection than the other variants (Fig. 4A). Apparently, the 43Yand 112F variants of TRIM5αhu exhibit mild decreases in the
ability to restrict N-MLV and HIV-1 infection, compared with
other TRIM5αhu variants. Conversely, the 136Q TRIM5αhu
variant consistently exhibited slightly more potent HIV-1-
restricting ability compared with the wild-type TRIM5αhu
protein (Fig. 4A). To corroborate these results, we established
three independent Cf2Th cell lines expressing each of the wt
TRIM5αhu, TRIM5αhu 43Yand TRIM5αhu 136Q proteins. The
cells, along with control cells transduced with the empty vector,
were incubated with HIV-1-GFP. As shown in Fig. 4B, the anti-
HIV-1 activity of the 43Y mutant was consistently weaker than
that of the wt TRIM5αhu protein and the anti-HIV-1 activity of
the 136Q protein was consistently more potent than that of wt
TRIM5αhu. All of the TRIM5αhu-mediated decreases in
susceptibility to N-MLV or HIV-1 infection were specific, as
the susceptibility of the Cf2Th cells expressing the TRIM5αhu
variants to B-MLV infection was similar (Fig. 3B).
TRIM5αrh exhibits more potent anti-HIV-1 activity than
TRIM5αhu (Stremlau et al., 2004). Residue 138 in TRIM5αrh,
which is equivalent to residue 136 in TRIM5αhu, is glutamine.
To determine whether the glutamine at this position contributes
to TRIM5αrh antiviral potency, we altered it to arginine. This
change, however, had little effect on the ability of TRIM5αrh to
restrict HIV-1 infection (Fig. 4B).
We conclude that naturally occurring variation in residues 43
and 136 of TRIM5αhu results in subtle but reproducible effects
on anti-HIV-1 potency.Discussion
Variation among the TRIM5α proteins of primate species
governs the ability to restrict infection by particular retro-
viruses (Hatziioannou et al., 2004a; Hofmann et al., 1999;
Keckesova et al., 2004; Song et al., 2005c; Stremlau et al.,
2004; Yap et al., 2004a). Evidence of positive selection
operating on TRIM5 supports the possibility that this gene has
evolved to contribute to antiviral immunity (Sawyer et al.,
2005; Song et al., 2005b; Ortiz et al., 2006). In this genetic
epidemiological study of five HIV-1 natural history cohorts,
we identified 12 common TRIM5 SNPs, five of which result
in amino acid changes. Several other, presumably rare, SNPs
were also identified. A high proportion of the identified SNPs
in the TRIM5-coding region involved non-synonymous
changes; however, this tendency was short of significant.
In African Americans, four TRIM5 alleles exhibited different
frequencies in HIV-1-infected and -uninfected individuals,
raising the possibility that they influence the risk of acquiring
HIV-1 infection. SNP2 in the non-coding exon 1 and SNP3 in
intron 1 were each associated with increased risk of infection.
Although the functional role of these SNPs is unknown, it is
possible that they are either in LD with causal SNPs elsewhere
in the gene or are themselves causal and may affect gene
regulation or alternative splicing. Because the variant alleles for
SNP2 and SNP3 are in negative LD and rarely occur together on
the same haplotype, their effects on HIV-1 susceptibility are
independent.
Fig. 4. Effect of expression of the TRIM5αhu variants on HIV-1 infection. (A)
Cf2Th cells expressing the wild-type (wt) and mutant TRIM5α proteins, or
control Cf2Th cells transduced with the empty pLPCX vector, were incubated
with various amounts of HIV-1-GFP. Cells were washed and returned to culture
for 48 h, and then subjected to FACS analysis with a FACScan (Becton
Dickinson). (B) For wt TRIM5αhu and each mutant TRIM5αhu protein (H43Yor
R136Q), three independent Cf2Th cell lines were created. Three Cf2Th lines
were also made by transduction with the empty pLPCX control vector. Cf2Th
cells expressing wt TRIM5αrh or TRIM5αrh Q136R were also created. Cells
were incubated with the indicated amounts of HIV-1-GFP. Cells were washed
and returned to culture for 48 h and then subjected to FACS analysis with a
FACScan (Becton Dickinson). The means and standard deviations derived from
the experiments using the three independently established cell lines are
indicated.
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glutamine 136 was more frequent in both HREU and SN
groups than in the SC group. The elevated frequency of this
allele in both HREU and SN groups suggests that an HIV-1-
protective effect may be afforded by this allele—and that this
protection applies to individuals who are subject to a range of
exposure frequencies. The TRIM5 allele encoding a TRIM5
protein with tyrosine 43 tended to be more frequent in
uninfected individuals. Any effects of 43Y and 136R are
independent because the two alleles do not occur together on
the same haplotype.
The effects of these four SNPs were observed only for the
African American group, almost all of whom reported injecting
drugs, but not for European Americans in our cohorts, although
the latter group has greater sample size. SNP2 was nearly absent
from EA; however, SNP3, SNP5 and SNP7 had either similar or
greater allele frequencies in EA. This suggests that any
modification of infection susceptibility afforded by particular
TRIM5 alleles may be restricted to particular population group
(s) or types of exposure. The diverse frequency distribution of
almost all SNPs and different haplotype structure in populations
could be responsible for the discrepancy. Such population-specific effects have previously been observed for other AIDS-
modifying genes (An et al., 2002, 2004; Gonzalez et al., 1999;
Winkler et al., 2004).
It is difficult to assess the significance of haplotypes and
correlated SNPs given the number of statistical comparisons.
We measured the overall significance of TRIM5 SNPs and
haplotypes by testing a multivariant logistic regression model
by a permutation test. The permutation test determines how
frequently one would see an overall association as strong as
that seen for the actual data under the null hypothesis of no
association of SNPs or haplotypes with HIV-1 infection. The
global corrected P value <0.05 for both SNPs and haplotypes
indicates that polymorphism in TRIM5 may affect HIV-1
infection susceptibility although no individual SNP or
haplotype reaches significance after correction for false
discovery (Storey and Tibshirani, 2003; Benjamini and
Hochberg, 1995).
Ultimately, associations between TRIM5 genotypes and
HIV-1 infection in humans require confirmation in multiple
studies. Recently, a study of the effects of TRIM5 poly-
morphisms on HIV-1 infection was conducted in a cohort
consisting primarily of European American men having sex
with men (Speelmon et al., 2006). None of the individual
TRIM5 SNPs identified in that study demonstrated an
association with HIV-1 susceptibility, consistent with our
results in European Americans. Speelmon and colleagues
found that a TRIM5 haplotype containing 136Q exhibited
increased frequency among HIV-1-infected subjects compared
with exposed seronegative individuals. This contrasts with the
apparently protective effect of 136Q in African Americans in
our study. Explanations for these different results include
differences in genetic background and type of exposure,
linkage with other genetic sequences that are responsible for
the phenotype, and spurious associations. Additional studies
should provide a more complete picture of the role of TRIM5
variation in susceptibility to HIV-1 infection. In agreement
with our results, Speelmon and colleagues (2006) found no
association between TRIM5 genotype and markers of clinical
progression. Apparently, once HIV-1 infection is established,
the contribution of variation in TRIM5αhu to outcome is
negligible.
The 136Q variant of TRIM5αhu was associated with
protection from HIV-1 infection in African Americans in our
study. Although we observed no significant difference in the
ability of TRIM5αhu proteins differing in residue 136 to
restrict N-MLV infection of tissue-cultured cells, the 136Q
TRIM5αhu variant was consistently superior to wt TRIM5αhu
in blocking HIV-1 infection. Although this HIV-1-restricting
phenotype is weak, it is consistent with the epidemiologic
observations. The mechanistic basis of this phenotype is
uncertain; the coiled coil domain in which arginine/glutamine
136 resides has been implicated in TRIM5α oligomerization
(Javanbakht et al., 2005; Mische et al., 2005; Perez-Caballero
et al., 2005). Of note, glutamine (or, in one case, glutamic
acid) is commonly found at residue 136 in the TRIM5α
proteins of most non-human primates, with the exception of
chimpanzees (Song et al., 2005b). Thus, most primates may
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respect to antiretroviral activity.
The 43Y variant was less effective at restricting HIV-1 and
N-MLV infections of tissue-cultured cells than the other
TRIM5αhu variants tested. This result corroborates those
recently reported by (Sawyer et al., 2006). The superior
antiretroviral activity of the TRIM5αhu protein with a histidine
43 residue, compared with that of the tyrosine 43 residue, in
this in vitro system is not consistent with the trend towards an
HIV-1-protective effect of 43Y observed in our the epidemio-
logical study. Of note, histidine is found at residue 43 of most
other non-human primate TRIM5α proteins (Song et al.,
2005b). Residue 43 is located in the RING domain of
TRIM5αhu; the RING domain contributes to, but is not
absolutely required for, the anti-HIV-1 activity of rhesus
monkey TRIM5α (Javanbakht et al., 2005). Although no
structural information is available for TRIM5α, the structure of
the RING domain of TRIM19 (PML) has been solved (Borden
et al., 1995). Assuming that the TRIM5 and TRIM19 RING
domains fold similarly, residue 43 of TRIM5α is predicted to
be well-exposed on the surface of the protein. Substitution of a
tyrosine for histidine in this surface-exposed location could add
hydrophobic character, increasing the tendency for aggregation.
TRIM5αhu 43Y formed more prominent cytoplasmic bodies in
the transfected Cf2Th cells than the other TRIM5αhu proteins.
Other studies have suggested that TRIM5α cytoplasmic bodies
represent pre-aggresomal structures that are not essential for
antiretroviral activity (Diaz-Griffero et al., 2006; Song et al.,
2005a). Thus, relative to other TRIM5αhu variants, 43Y may
exhibit increased propensity to coalesce into cytoplasmic
bodies and may be less available in the forms required for
antiretroviral activity. The consequences of the observed
modest decreases in the ability of TRIM5αhu 43Y to restrict
HIV-1 or N-MLV infection in our experimented system will
need to be examined in more natural contexts. Factors such as
the level of TRIM5αhu expression and the co-expression of
other TRIM5α alleles might influence the phenotype of
TRIM5αhu H43Y, for example. Such variables may account
for the inconsistencies between the functional and epidemio-
logical results for 43Y.
The TRIM5αhu 112F variant exhibited a slight decrease in
antiretroviral activity in tissue-cultured cells, relative to the wt
TRIM5αhu protein. This fairly common variant involves the B-
box 2 domain, which has been shown to be essential for the
ability of rhesus monkey TRIM5α to block HIV-1 infection
(Javanbakht et al., 2005). The precise contribution of residue 112
to antiretroviral activity of TRIM5α remains to be determined.
We did not observe any evidence of an in vivo effect of changes
in this TRIM5α residue on susceptibility to HIV-1 infection or
progression to AIDS, consistent with the results of another study
(Speelmon et al., 2006).
Future studies may clarify the circumstances in which TRIM5
polymorphisms exert effects on susceptibility to HIV-1 infec-
tion, and the mechanisms of these effects. Awareness of
variation in human TRIM5α proteins or in the regulation of
this protein may be important in attempts to manipulate this
antiretroviral factor to our advantage.Materials and methods
Study participants
Study subjects were enrolled in five natural history HIV/
AIDS cohorts: AIDS Link to the Intravenous Experience
(ALIVE; Vlahov et al., 1998), Multicenter AIDS Cohort Study
(MACS; Buchbinder et al., 1994; Kaslow et al., 1987), the San
Francisco City Clinic Study (SFCC; Buchbinder et al., 1994),
Hemophilia Growth and Development Study (HGDS; Goedert
et al., 1989; Hilgartner et al., 1993) and the Multicenter
Hemophilia Cohort Study (MHCS; Goedert et al., 1989). The
subjects used in this report consisted of HIV-1 seroconverters
(SC), seroprevalents (SP) and seronegatives (SN) for a total of
3604 participants (2171 EA and 1433 AA). The number of
subjects studies in each disease category was as follows:
SC=644 EA, 295 AA; SN=571 EA, 420 AA; and HREU=145
EA, 80 AA. Seroprevalents were included for allele frequency
determination and haplotype inference but were not used in the
association analysis.
The date of seroconversion after study enrollment was
estimated as the midpoint between the last seronegative and first
seropositive HIV-1 antibody test; only individuals with less than
2 years elapsed time between the two tests were included. The
censoring date was December 31, 1995, for the MACS, MHCS,
HGDS or SFCC or July 31, 1997, for the ALIVE cohort to
avoid potential confounding by highly active anti-retroviral
therapy (HAART). Because uptake of HAART was delayed in
the ALIVE cohort (Celentano et al., 2001), the later censoring
date was used.
High-risk exposed uninfected (HREU) subjects were those
80 African Americans and 145 European Americans with high-
risk exposure through sharing of injection equipment (Vlahov
and Polk, 1988), who had anal receptive sex with multiple
partners (Detels et al., 1994) or transfusions with Factor VIII
clotting factor prior to 1984, when heat treatment was initiated
(Salkowitz et al., 2001). Seronegative subjects (n=420 and 571
for AA and EA, respectively) are those enrolled in the cohorts
who remained HIV seronegative despite ongoing or prior risk
activity. In addition, DNAs from 193 HIV-1-seropositive
individuals and 79 seronegative blood donors from the Western
Cape of South African of Xhosa descent were included for
polymorphism discovery (Petersen et al., 2005). We included
DNA from 92 normal Chinese Han to determine TRIM5 allele
frequencies for this major Asian population.
The study protocols were approved by the Institutional
Review Boards of participating institutions and informed
consent was obtained from all study participants.
Identification of DNA polymorphisms
Genetic variation in the TRIM5 gene was identified by
several methods. SNPs were identified from the Center for
Biotechnology Information (NCBI) dbSNP Database (Sherry et
al., 2001), by re-sequencing, and by a heteroduplex assays
designed to detect nucleotide mismatches. To discover unre-
ported TRIM5 polymorphisms, we used a screening panel
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and 94 from African Americans (AA) comprised of rapid
progressors (clinical AIDS within 3 years of seroconversion),
slow progressors (CD4<200 at 12 or more years after
seroconversion) and HREUs (confirmed multiple exposures).
A non-isotopic RNA cleavage assay (NIRCA) in conjunction
with re-sequencing was performed to detect polymorphisms
(Goldrick et al., 1996): PCR primers were designed to cover the
putative promoter, 5′ untranslated region (UTR), all exons and
3′ UTR, based on the genomic sequence ac109341 (Supple-
mentary Table 3a). The 5′ upstream region (or putative
promoter region) sequenced covers 1.2 kb upstream of the
first base of the TRIM5 mRNA sequence (GenBank accession
number NM_033034). The exons were amplified with primers
located in the introns.
To discover rare genetic variants associated with HIV-1
disease or polymorphisms in diverse populations, we re-
sequenced DNA (n=2293) using primers listed in Supplemen-
tary Table 3b for coding exons 2 and 8 (unless otherwise
indicated) from the following groups: U.S.-based normal
donors (n=359); unrelated founders from the CEPH families
(n=93); the Human Diversity panel (n=368); and participants
from the 5 natural history AIDS cohorts including seroconver-
ters (n=420); at-risk seronegatives for all exons except exons 1
and 5, and intron 7 (n=344); and seroprevalent progressing to
AIDS in within 5 years of study entry for all exons except exons
1, 5 and 7 (n=188) or who remaining AIDS-free for 10 or more
years (n=90). Exon 8 containing the B20.3 (SPRY) domain was
also re-sequenced in South Africans of Xhosa descent (n=272)
(Petersen et al., 2005).
Genotyping of genetic variants
Genotypes were determined by TaqMan or PCR-restriction
fragment length polymorphism (RFLP) assays for participants
enrolled in the 5 natural history cohorts. TaqMan allelic
discrimination assays to determine genotypes were designed
by using the Primer Express software or by the assay-by-
demand or the assay-by-design service offered by Applied
Biosystems (Foster City, CA). Genotyping was performed using
TaqMan assays according to the manufacturer's protocols
(Applied Biosystems, Foster City, CA). Primer and probe
combinations are listed in Supplementary Table 4. TaqMan
genotypes were automatically called and plotted using the SDS
2.1 software (Applied Biosystems, Foster City, CA), based on a
two-parameter plot using fluorescence intensities of FAM and
VIC dye-labeled MGB probes. Eight water controls were
included on each plate to monitor potential PCR contamination
and 10% of the DNA samples were duplicated. Three SNPs
were genotyped by PCR- RFLP assays. PCR was performed in
20 μl reactions consisting of 20 ng of genomic DNA using
TaqGold polymerase protocols (Applied Biosystems, Foster
City, CA) and PCR buffer (Roche, Indianapolis, IN). PCR was
carried out with 35 cycles of denaturing at 94 °C for 30 s,
annealing at 58 °C for 30 s, and extension at 72 °C for 45 s. PCR
primer sequences and restriction enzymes used for each SNP are
listed in Supplementary Table 4.Statistical analysis
The genetic effects of SNPs on HIV-1 infection susceptibility
were assessed by comparing allelic and genotypic frequencies
between (1) HIV-1 high-risk exposed uninfected (HREU)
individuals and HIV-1+ seroconverters (SC) and (2) HIV-1
seronegatives (SN) belonging to HIV-1 risk groups and
seroconverters (SC), by using the chi-square test or Fisher's
exact test. The significance level was P<0.05 for two-tailed
tests. Genetic risk magnitudes were measured by calculating
odds ratios (ORs) with 95% confidence intervals (CIs). The
Mantel–Haenszel test and proportional odds logistic regression
were used to test for the trend among three groups: SC, SN and
HREU. Individuals carrying the CCR5 Δ32/Δ32 genotype
were excluded from the analysis.
A permutation test was used to compare the null hypothesis
of no effect of TRIM5 SNPs or haplotypes with the most natural
a priori alternate hypothesis, that there are effects of TRIM5
variants that are additive for the genetic factors and progressive
in susceptibility to infection. A proportional odds logistic
regression was done (the polr function in R, using automatic
forward selection by the Aikike information criterion (AIC)
(stepAIC)) with TRIM5 SNPs or haplotypes as explanatory
variables, and ordinal susceptibility to infection (level 1:
HREU; level 2: other uninfected; level 3: seroconverters) as
the outcome variable. SNPs with minor allele frequency <0.05
were omitted. The results with actual data were compared with
those from 5000 random permutations of the infection data,
with the genotype data held fixed. Significance was measured as
the proportion analyses of permuted for which the AIC was≤ to
the AIC for the actual data.
Kaplan–Meier survival statistics and the Cox proportional
hazards model were used to assess the effects of SNPs and
haplotypes on the rate of progression to AIDS. Three endpoints
were evaluated: time to less than 200 CD4+ cells/mm3
(CD4<200); AIDS-1987 (Centers for Disease Control, 1987);
and the expanded AIDS-1993 CDC case definitions (Centers for
Disease Control, 1992) and AIDS-related death. AIDS-93
definition is defined as CD4<200 or any AIDS-defining
condition in an HIV-1-infected person. The significance of
genotypic associations and relative hazards (RH) for dominant
and recessive genetic models were determined. Participants
were stratified by sex and by age at seroconversion: 0–20,
>20–40 and over 40 years (O'Brien et al., 2000). All P values
are 2-tailed.
To assess the impact of the multiple comparison tests
performed in our analysis, we estimated the Q value measuring
false discovery rate (FDR), which is defined as the proportion of
statistical tests called significant that are actually false positive
(Storey and Tibshirani, 2003). An FDR of 5% means that 5% of
the significant associations are false positive. We calculated Q
value considering all the SNP association analyses of each SNP
in AA and EA (Table 1) (Storey et al., 2003).
Linkage disequilibrium (LD) between all pairs of biallelic
loci was quantified using the absolute value of Lewontin's
D′ (Lewontin, 1964; Long et al., 1995). Absolute values
of D′ range from 0 for independence to 1 for complete
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inferred by the expectation maximization algorithm (Long et
al., 1995). Fst estimates between EA and AA for the SNP
alleles were calculated as described by Weir and Cockerham
(1984).
Cells and antibodies
Cf2Th canine thymocytes were obtained from the American
Type Culture Collection. The generation of a cDNA containing
the amino-acid-coding sequence of the wild-type (wt) human
TRIM5α gene was described previously (Stremlau et al.,
2004). Cells stably expressing TRIM5αhu variants were created
using a retroviral transduction system. Retroviral vectors
encoding the TRIM5αhu variants were created using the
pLPCX vector (Stratagene). The pLPCX-TRIM5α vectors
contain only the amino-acid-coding sequence of the TRIM5αhu
cDNA. The TRIM5αhu protein possesses a C-terminal epitope
tag derived from influenza virus hemagglutinin (HA). Recom-
binant viruses were produced in 293T cells by cotransfecting
these pLPCX plasmids with the pVPack-GP and pVPack-VSV-
G packaging plasmids (Stratagene). The pVPack-VSV-G
plasmid encodes the vesicular stomatitis virus (VSV) G
envelope glycoprotein, which allows efficient entry into a
wide range of vertebrate cells (Beyer et al., 2002; Hofmann et
al., 1999; Yee et al., 1994). The resulting virus particles were
used to transduce ∼1×105 Cf2Th cells in the presence of
polybrene (5 μg/ml). Cells were selected in medium supple-
mented with 1 μg/ml of puromycin (Sigma).
The rat anti-HA antibody 3F10 was obtained from Roche.
The anti-rat IgG conjugated with FITC was obtained from Santa
Cruz.
Western blotting
Steady-state levels of TRIM5α proteins in the cell were
determined by Western blotting with an anti-HA antibody, as
described previously (Song et al., 2005c).
Immunofluorescence confocal microscopy
Cf2Th cells expressing the wild-type or variant TRIM5αhu
proteins were cultured overnight on Lab-Tek II Chamber Slides
(Nalge Nunc International). Following fixation for 15 min in
Cytofix/Cytoperm (BD Biosciences) and permeabilization for
15 min in Perm/Wash (BD Biosciences), the cells were
incubated for 1 h with rat anti-HA 3F10 antibody (Roche).
The cells were then incubated with an anti-rat IgG conjugated
with FITC (Santa Cruz) and examined by confocal fluorescence
microscopy.
Infection with viruses expressing GFP
Recombinant viruses (HIV-1-GFP, N-MLV-GFP and B-
MLV-GFP) expressing the humanized Renilla reniformis green
fluorescent protein (GFP) were prepared as previously
described (Perron et al., 2004; Stremlau et al., 2004). The
viral stocks were quantified by measuring reverse transcriptase
activity, as described previously (Rho et al., 1981). Cf2Thcells expressing the wild-type (wt) and mutant TRIM5α
proteins, or control Cf2Th cells transduced with the empty
pLPCX vector, were incubated with various amounts of the
recombinant viruses, as described (Perron et al., 2004;
Stremlau et al., 2004). For infections, 3×104 Cf2Th cells
seeded in 24-well plates were incubated with virus for 24 h.
Cells were washed and returned to culture for 48 h and then
subjected to FACS analysis with a FACScan (Becton
Dickinson).
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